- Thermo Fisher Scientific has opened a 4,000-square-foot Bioprocess Design Center at its Plainville, Massachusetts site to support biologics development and scale-up.
- The facility integrates end-to-end bioproduction capabilities and provides hands-on collaboration, training, and technical support for customers.
Thermo Fisher Scientific Inc. announced the opening of a new Bioprocess Design Center (BDC) at its Plainville, Massachusetts site to support customers in developing and scaling biologics. The 4,000-square-foot facility is designed to provide integrated bioproduction capabilities and hands-on collaboration to accelerate process development and enable faster progression of therapies to market.
The center offers a full bioproduction workflow, including media, cell line development, single-use systems, chromatography, filtration, purification, and analytics. It is intended to help customers optimize processes, improve scalability, and reduce development timelines. The facility supports a range of biologics, including vaccines and cell and gene therapies.
Onsite specialists provide demonstrations, training, and technical consulting. Customers can work directly with Thermo Fisher experts to test and refine processes, validate concepts, and address development challenges. The company stated that this collaborative approach is designed to support transition from development to scalable production.
“Our new Bioprocess Design Center brings together Thermo Fisher’s experts and customers to tackle some of the most complex challenges in bioprocessing, demonstrating how collaboration and shared innovation can accelerate therapeutic development.”
Daniella Cramp, senior vice president and president, BioProduction and Customer Excellence at Thermo Fisher Scientific
The new center complements Thermo Fisher’s existing capabilities at the Plainville site, including sterile fill-finish and viral vector services. It also supports the company’s broader CDMO and contract manufacturing offerings through its Accelerator™ Drug Development platform, which provides integrated services across the drug development lifecycle.
